Can Europe catch up in the biotech race with the US and China?

Europe boasts world-class biotech research, yet the economic success generated from these innovations often materializes elsewhere. To counter this trend, a new European Biotech Act is being introduced. The legislation aims to keep companies and their production facilities within Europe, preventing a common pattern of companies relocating abroad after initial discoveries.

Despite a wealth of ideas, excellent research, and a well-trained pool of young scientists, Europe has consistently faced challenges in the crucial step of transforming scientific breakthroughs into thriving businesses. This new act is designed to address this long-standing issue and foster a more robust domestic biotech industry.

The continent's strength lies in its research capabilities and the talent of its scientists. The challenge now is to build a more effective ecosystem that supports the commercialization of these scientific advancements, ensuring that the economic benefits remain within Europe.